UY34078A - PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER - Google Patents

PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER

Info

Publication number
UY34078A
UY34078A UY0001034078A UY34078A UY34078A UY 34078 A UY34078 A UY 34078A UY 0001034078 A UY0001034078 A UY 0001034078A UY 34078 A UY34078 A UY 34078A UY 34078 A UY34078 A UY 34078A
Authority
UY
Uruguay
Prior art keywords
methods
pharmaceutical compositions
treat cancer
cancer
treat
Prior art date
Application number
UY0001034078A
Other languages
Spanish (es)
Inventor
Rosen Oliver
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34078A publication Critical patent/UY34078A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SIN ESCANEO
UY0001034078A 2011-05-17 2012-05-17 PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER UY34078A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486851P 2011-05-17 2011-05-17
US201161538246P 2011-09-23 2011-09-23

Publications (1)

Publication Number Publication Date
UY34078A true UY34078A (en) 2012-11-30

Family

ID=47177338

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034078A UY34078A (en) 2011-05-17 2012-05-17 PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER

Country Status (7)

Country Link
EP (1) EP2709614A4 (en)
JP (1) JP2014513730A (en)
AR (1) AR086444A1 (en)
CA (1) CA2836277A1 (en)
TW (1) TW201309291A (en)
UY (1) UY34078A (en)
WO (1) WO2012158884A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3124481T3 (en) 2010-02-16 2018-05-07 Aragon Pharmaceuticals Inc ANDROGEN RECEPTOR MODULATORS AND APPLICATIONS THEREOF
JP5998137B2 (en) 2010-08-04 2016-09-28 ペルフィキュア ファーマシューティカルズ，インコーポレイテッド Combination therapy to treat prostate cancer
UY33740A (en) * 2010-11-18 2012-05-31 Takeda Pharmaceutical METHOD FOR TREATING BREAST CANCER AND OVARIAN CANCER
IL312316A (en) 2012-09-26 2024-06-01 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (en) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
WO2014158875A1 (en) * 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
KR20200070334A (en) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
MX2008012492A (en) * 2006-03-29 2008-12-12 Univ California Diarylthiohydantoin compounds.
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
CL2008003198A1 (en) * 2007-10-29 2009-12-18 Takeda Pharmaceuticals Co Pharmaceutical composition comprising a steroid c17,20 lyase inhibitor; and use for the treatment of androgen-independent prostate cancer.

Also Published As

Publication number Publication date
TW201309291A (en) 2013-03-01
AR086444A1 (en) 2013-12-11
JP2014513730A (en) 2014-06-05
EP2709614A4 (en) 2015-04-15
EP2709614A1 (en) 2014-03-26
WO2012158884A1 (en) 2012-11-22
CA2836277A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
UY34078A (en) PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT CANCER
CL2018003282A1 (en) Methods and compositions for the treatment of cancers resistant to inhibitors of the non-erk mapk pathway
CL2015001157A1 (en) Compositions and methods to treat proteinopathies.
CO7111289A2 (en) Metalloenzyme inhibitor compounds
CL2015001392A1 (en) Compounds and their methods of use
CO6900118A2 (en) Methods to treat cancer by the use of pk-1e-binding antagonists and mek inhibitors
BR112013028281A2 (en) nampt inhibiting compounds and compositions
UY34822A (en) COMPOSITIONS AND METHODS TO SILENCE GENETIC EXPRESSION
CO7020912A2 (en) Bromodomain Inhibitors
BR112014001440A2 (en) New Compositions and Methods for the Treatment of Prostate Cancer
BR112013025006A2 (en) compositions and methods for inhibiting tmprss6 gene expression
EP2943565A4 (en) Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
DK2707030T3 (en) CANCER TREATMENTS
BR112013033720A2 (en) method to treat eczema
ES2579990T8 (en) Methods and compositions to treat metabolic syndrome
BR112014011009A2 (en) dual met and vegf inhibitor to treat cancer
CO7151512A2 (en) Nampt inhibitors
BR112014006419A2 (en) Methods to Treat a Cancer Patient, Kit and Article
BR112015028115A2 (en) methods and compositions for cancer treatment
GT201300045S (en) APPARATUS TO HAIR HAIR
BR112013008528A2 (en) Methods To Treat Psoriasis
HK1216610A1 (en) Compositions and methods for transdermal delivery of non-steroidal anti-inflammatory agents
BR112014026326A2 (en) composition for treatment of metabolic disorders
BR112015000099A2 (en) compositions and methods for enhancing mobilization and proliferation of blastomer-like stem cells
CR20130246A (en) COMPOSITIONS AND METHODS TO TREAT CANCER USING A PI3K INHIBITOR AND A MEK INHIBITOR

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019